Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2018-10-01 / Front Immunol 2018;9:2265Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
/in Breast Cancer, Checkpoint-Inhibitors, Hyperthermia, International Publications /von 2018-09-07 / Integr Cancer Ther 2018 12;17(4):1297-1303Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2018-08-29 / CNS Oncol 2018 07;7(3):CNS22Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
/in Checkpoint-Inhibitors, International Publications /von 2018-08-22 / Expert Rev Vaccines 2018 08;17(8):697-705Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2018-06-19 / Oncotarget 2018 Jun;9(47):28702-28716Immunotherapy of Hepatocellular Carcinoma
/in Checkpoint-Inhibitors, Dendritic Cells, Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus /von 2018-04-20 / Oncol Res Treat 2018;41(5):292-297PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2018-03-05 / J. Clin. Invest. 2018 Apr;128(4):1413-1428Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2018-03-01 / Front Immunol 2018;9:394Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
/in Acute Leukemia, Checkpoint-Inhibitors, Chronic Leukemia, Dendritic Cells, International Publications /von 2018-02-15 / Blood Rev. 2018 Jul;32(4):312-325
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de